Tenax Therapeutics (TENX) Income from Continuing Operations (2010 - 2026)
Tenax Therapeutics recorded quarterly Income from Continuing Operations of 15712000.0 in Q1 2026, down 1.17% quarter-over-quarter from 15531000.0 in Q4 2025, and down 50.96% year-over-year from 32039673.98 in Q1 2025.
Tenax Therapeutics' Income from Continuing Operations history runs 16 years deep, the most recent figure standing at 15712000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 50.96% year-over-year to 15712000.0; the TTM figure through Mar 2026 stood at 57870000.0 (down 139.01% YoY), while the FY2025 annual figure was 52566000.0, down 198.62% from the prior year.
- Income from Continuing Operations came in at 15712000.0 for Q1 2026 at Tenax Therapeutics, down from 15531000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 2917116.0 in Q3 2022 to a low of 15789000.0 in Q3 2025.
- A 5-year average of 5019392.47 and a median of 3799000.0 in 2024 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations surged 104.1% in 2022 and plunged 580.63% in 2023, its largest moves.
- Tenax Therapeutics' Income from Continuing Operations stood at 2554624.0 in 2022, then slumped by 580.63% to 12278314.0 in 2023, then soared by 48.96% to 6267000.0 in 2024, then slumped by 147.82% to 15531000.0 in 2025, then decreased by 1.17% to 15712000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 15712000.0, 15531000.0, and 15789000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Tenax Therapeutics | 542.72 Mn | 542.72 Mn | - | -15.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -15.71 Mn |
| Dec 31, 2025 | -15.53 Mn |
| Sep 30, 2025 | -15.79 Mn |
| Jun 30, 2025 | -10.84 Mn |
| Mar 31, 2025 | -10.41 Mn |
| Dec 31, 2024 | -6.27 Mn |
| Sep 30, 2024 | -3.96 Mn |
| Jun 30, 2024 | -3.58 Mn |
| Mar 31, 2024 | -3.80 Mn |
| Dec 31, 2023 | -12.28 Mn |
| Sep 30, 2023 | 1.96 Mn |
| Jun 30, 2023 | 1.37 Mn |
| Mar 31, 2023 | -1.55 Mn |
| Dec 31, 2022 | 2.55 Mn |
| Sep 30, 2022 | 2.92 Mn |
| Jun 30, 2022 | 2.86 Mn |
| Mar 31, 2022 | 2.72 Mn |
| Dec 31, 2021 | -62.24 Mn |
| Sep 30, 2021 | 3.80 Mn |
| Jun 30, 2021 | 1.96 Mn |
| Mar 31, 2021 | 23.75 Mn |
| Dec 31, 2020 | 2.83 Mn |
| Sep 30, 2020 | 2.23 Mn |
| Jun 30, 2020 | 2.14 Mn |
| Mar 31, 2020 | 2.67 Mn |
| Dec 31, 2019 | -14.30 Mn |
| Sep 30, 2019 | 2.26 Mn |
| Jun 30, 2019 | 1.82 Mn |
| Mar 31, 2019 | 1.66 Mn |
| Dec 31, 2018 | -11.56 Mn |
| Sep 30, 2018 | 1.55 Mn |
| Jun 30, 2018 | 1.89 Mn |
| Mar 31, 2018 | 1.22 Mn |
| Dec 31, 2017 | -17.03 Mn |
| Sep 30, 2017 | 1.31 Mn |
| Jun 30, 2017 | 3.01 Mn |
| Mar 31, 2017 | 3.50 Mn |
| Dec 31, 2016 | -67.53 Mn |
| Sep 30, 2016 | 4.50 Mn |
| Jun 30, 2016 | 4.67 Mn |
| Mar 31, 2016 | -5.71 Mn |
| Dec 31, 2015 | -10.43 Mn |
| Sep 30, 2015 | -3.10 Mn |
| Jun 30, 2015 | -4.87 Mn |
| Apr 30, 2013 | -1.86 Mn |
| Jan 31, 2013 | -2.41 Mn |
| Oct 31, 2012 | -1.55 Mn |
| Jul 31, 2012 | -3.60 Mn |
| Apr 30, 2012 | -2.63 Mn |
| Jan 31, 2012 | -7.22 Mn |
| Oct 31, 2011 | -2.93 Mn |
| Jul 31, 2011 | -2.86 Mn |
| Apr 30, 2011 | 2.85 Mn |
| Jan 31, 2011 | 2.80 Mn |
| Oct 31, 2010 | 2.05 Mn |
| Jul 31, 2010 | 3.02 Mn |